Do Acne Drugs for PCOS Affect Mental Health? Large Database Study Probes the Question

Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, and its reach extends far beyond the ovaries. Characterized by irregular ovulation, elevated androgen levels, and polycystic ovarian morphology on ultrasound, the condition frequently announces itself through the skin. Hirsutism, androgenetic alopecia, and persistent acne are among the most visible manifestations, and for many patients the dermatologist is the first clinician to suspect that something hormonal is at work. A new research letter published in the Archives of Dermatological Research by Caitlyn Curley, Dylan Wambold, and Erum N. Ilyas of Drexel University College of Medicine turns the spotlight on an underexamined corner of this landscape: the psychiatric outcomes of patients with polycystic ovary syndrome-associated acne who are treated with spironolactone, oral contraceptives, or both.

The rationale for the study rests on a convergence of two clinical realities. First, the psychological burden of polycystic ovary syndrome is well documented in the literature. Women with the syndrome carry elevated rates of depression and anxiety compared with matched controls, and the distress is not merely a reaction to cosmetic concerns. Insulin resistance, obesity, chronic anovulation, and hyperandrogenism all contribute to a metabolic and endocrine milieu that researchers have increasingly linked to mood disorders. Earlier work, including a study by Sivayoganathan and colleagues published in Human Fertility, found that full investigation of patients presenting with polycystic ovary syndrome across four different clinical specialties revealed significant differences in morbidity and a troubling rate of undiagnosed disease, underscoring how often the syndrome’s systemic dimensions slip through the cracks of specialty-based medicine.

Second, the treatments themselves have plausible and, in some cases, documented effects on mood. Spironolactone, a potassium-sparing diuretic that blocks aldosterone and antagonizes androgen receptors, has become a mainstay of hormonal acne therapy in dermatology clinics, particularly for women whose acne flares along the jawline and resists conventional antibiotics and topicals. But the drug’s pharmacological reach does not stop at the sebaceous gland. A double-blind, placebo-controlled trial by Wang and colleagues in the mid-1990s found that spironolactone improved symptoms of premenstrual syndrome, suggesting a direct or indirect effect on the neuroendocrine pathways that govern cyclical mood changes. More recently, an observational case series by Wernze and Herdegen reported long-term benefits of spironolactone on pain, mood, and quality of life in women with fibromyalgia, hinting that the drug’s central nervous system effects may be broader than its dermatological reputation implies.

Oral contraceptives occupy an equally complicated position in this conversation. Combined formulations containing ethinylestradiol and anti-androgenic progestins such as drospirenone or dienogest are approved or widely used for acne, and they work by suppressing ovarian androgen production and increasing sex hormone-binding globulin, thereby reducing free testosterone. Yet the psychiatric profile of hormonal contraception has been the subject of intense public and scientific debate, with large pharmacoepidemiological studies over the past decade examining associations between contraceptive use and subsequent depression diagnoses, particularly in adolescents. A 2025 study by Palacio-Cardona and colleagues in the International Journal of Women’s Dermatology specifically assessed the contribution of a low-dose ethinylestradiol and dienogest combination to acne improvement and its perceived psychological effects in young university women, reflecting growing interest in whether clearing the skin translates into measurable psychological benefit.

Against this backdrop, the Drexel team asked a deceptively simple question: when patients with polycystic ovary syndrome-associated acne are treated with spironolactone, oral contraceptives, or the combination, what happens to their psychiatric outcomes? To answer it, the researchers turned to TriNetX, a federated health research network that aggregates de-identified electronic health record data from large numbers of healthcare organizations, primarily in the United States. TriNetX has become an increasingly popular tool for retrospective cohort studies because it allows investigators to define cohorts using standardized diagnostic and procedural codes, apply inclusion and exclusion criteria, and compare outcomes between exposed and unexposed groups across a dataset far larger than any single institution could provide. The platform’s scale is both its greatest strength and the source of its characteristic limitations, since the underlying data reflect real-world clinical documentation rather than the controlled conditions of a prospective trial.

The retrospective cohort design deserves attention in its own right. Rather than randomizing patients to treatment arms, the investigators identified patients with the relevant diagnoses and exposures in the historical record and compared psychiatric outcomes across treatment groups. This approach captures clinical reality, including the prescribing patterns, comorbidities, and patient populations that never make it into randomized trials, but it also introduces the perennial challenge of confounding. Patients who receive spironolactone may differ systematically from those who receive oral contraceptives in age, contraceptive intent, disease severity, metabolic profile, or baseline psychiatric history, and any of these differences could influence downstream mental health outcomes independently of the drugs themselves. Propensity matching and covariate balancing, the standard tools for mitigating such bias in database studies, become essential to interpreting any observed differences between groups.

The study’s framing within dermatology is significant for a reason that extends beyond academic taxonomy. Dermatologists prescribe a substantial share of the spironolactone and hormonal contraception used for acne, often as the sole prescriber managing these medications for patients whose underlying polycystic ovary syndrome may be undiagnosed or managed elsewhere, if at all. If these medications carry meaningful psychiatric effects, whether protective or adverse, the dermatology clinic becomes an unexpected frontline for mental health surveillance. Conversely, if clearing disfiguring acne produces measurable psychological improvement, that finding would strengthen the case for aggressive early treatment of a condition that is sometimes dismissed as merely cosmetic. The research letter, which the authors note was exempt from institutional review board oversight as a de-identified database study and was composed without the use of artificial intelligence, reflects a deliberate effort to bring quantitative evidence to a question that has largely been addressed through small studies, patient surveys, and clinical intuition.

It is worth being clear about what a study of this kind can and cannot establish. Retrospective database analyses identify associations within the recorded data; they cannot prove causation, and the psychiatric diagnoses captured in electronic health records depend on patients seeking care, clinicians documenting systematically, and coding practices that vary across institutions. The direction of any observed association is also vulnerable to reverse causation: patients whose mood deteriorates may be more likely to seek medical attention, receive new diagnoses, or have their records enriched with psychiatric codes, irrespective of any drug effect. These caveats are not reasons to dismiss the work but rather the essential context in which its findings must be weighed, and they explain why the authors frame the study as a contribution to an emerging evidence base rather than a definitive answer.

Nevertheless, the questions the study raises are timely and, for many patients, deeply personal. Online communities dedicated to polycystic ovary syndrome are filled with accounts of mood changes attributed to hormonal treatments, and clinicians routinely field questions about whether spironolactone causes depression or whether birth control pills will worsen anxiety. The scientific literature has offered only partial and sometimes contradictory guidance, with studies of individual drugs in different populations, at different doses, and with different outcome measures producing a patchwork that is difficult to translate into clinical advice. A cohort study that directly examines psychiatric outcomes in the specific population of polycystic ovary syndrome patients being treated for acne addresses precisely the population in which these questions arise most often in practice.

The Drexel study also fits into a broader movement within dermatology toward recognizing the specialty’s psychological dimensions. Acne vulgaris itself is associated with increased rates of depression, anxiety, and even suicidality, and the perceived psychological effects of acne treatment have become an explicit outcome in contemporary trials, as the Palacio-Cardona study demonstrates. As large-scale health data networks make it feasible to follow hundreds of thousands of patients across years of care, the field is gaining the statistical power to detect effects that smaller studies could only glimpse. Whether spironolactone and oral contraceptives ultimately prove to be psychiatrically neutral, protective, or harmful in this population, studies of this design represent the kind of evidence that will be needed to answer a question that matters to the millions of patients navigating both the skin and the mood consequences of polycystic ovary syndrome. The research letter, published as volume 318, article number 429 of the Archives of Dermatological Research, with no external funding and no relevant disclosures reported by the authors, is a compact but pointed addition to that effort.

Subject of Research: Psychiatric outcomes of hormonal acne treatments in polycystic ovary syndrome

Article Title: Psychiatric outcomes in PCOS-associated acne patients using spironolactone and/or oral contraceptives: a retrospective cohort TriNetX study

Article References: Curley, C., Wambold, D., & Ilyas, E. N. (2026). Psychiatric outcomes in PCOS-associated acne patients using spironolactone and/or oral contraceptives: a retrospective cohort TriNetX study. Archives of Dermatological Research, 318(1), Article 429. https://doi.org/10.1007/s00403-026-04896-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04896-x

Keywords: polycystic ovary syndrome, PCOS, acne, spironolactone, oral contraceptives, psychiatric outcomes, depression, anxiety, TriNetX, retrospective cohort study, dermatology, hormonal therapy